Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 31Active not recruiting 10Not yet recruiting 8Completed 8Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 129Breast Neoplasms 113Neoplasms 97Neoplasm Metastasis 78Melanoma 73Leukemia, Myeloid, Acute 69Colorectal Neoplasms 69Prostatic Neoplasms 60Multiple Myeloma 52Lung Neoplasms 52Ovarian Neoplasms 51Squamous Cell Carcinoma of Head and Neck 46Triple Negative Breast Neoplasms 42Recurrence 41Carcinoma, Renal Cell 39Carcinoma, Hepatocellular 39Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 35Brain Neoplasms 34Lymphoma 31Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Leukemia 29Lymphoma, Large B-Cell, Diffuse 28Head and Neck Neoplasms 28Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immunoglobulin Light-chain Amyloidosis × 1 year × Clear all
NCT05839626 2026-05-27

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Sanofi

Phase 1 Terminated
32 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡